DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
about
α-Synuclein modifies huntingtin aggregation in living cellsNutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathwayFrequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson diseaseVisual hallucinations: differential diagnosis and treatmentNeuropathology of non-Alzheimer degenerative disordersGenetics Underlying Atypical Parkinsonism and Related Neurodegenerative DisordersDisease-modifying therapeutic directions for Lewy-Body dementiasNeurophysiological biomarkers for Lewy body dementiasNeuropathological alterations in Alzheimer diseaseBiomarkers in dementia: clinical utility and new directionsTime to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Concomitant pathologies among a spectrum of parkinsonian disordersParkinson Disease and Dementia.Treatment of psychosis and dementia in Parkinson's disease.Biomarkers for cognitive impairment and dementia in elderly people.Neuropathologic substrates of Parkinson disease dementia.Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies.Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysisMagnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies.The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set.Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination.Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease DementiaPET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyRapidly progressive diffuse Lewy body disease.Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective studyLewy body dementia: caregiver burden and unmet needsNovel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentBiomarkers for cognitive impairment in Parkinson disease.Contribution of vascular pathology to the clinical expression of dementia.Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS methodProdromal clinical manifestations of neuropathologically confirmed Lewy body diseaseA novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder.The spectrum of cognitive impairment in Lewy body diseasesGaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.Lewy body dementia: the caregiver experience of clinical care.Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia.Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.
P2860
Q24298430-9621168C-DBA1-416F-9673-1CB614201B7AQ24306217-6E7B1332-7F90-428B-A9F4-ED19CD223DC7Q24646422-002864D0-3D8A-469A-887A-A3AA6D231A49Q24653561-37C6C115-96ED-45DF-951A-54057F30238EQ24657571-5D29879D-36E2-471C-9159-3FDF7917EF9FQ26779001-98099918-CDD9-47B4-AAA5-CFE7AA779D3BQ26782907-4AB581F7-47B7-47DD-8F05-3582FFD9D738Q26800048-BABB1444-1629-4EDD-85DB-DB9AD7CD8429Q27003314-9013C1FE-A3F9-408D-8012-897386A07BA4Q27007086-02F3B631-DEE0-453B-842E-11C790AE07B7Q27686808-4FBE8B4A-1287-47DF-83BE-5FC85372D8DDQ27686837-E1208FB6-860E-49A8-BA22-5EEDCB1520D7Q28236077-F3E6CE14-546A-4344-A340-9932AABE7299Q30248574-05BA4A43-1C05-4143-ADC1-60B16F01FFEEQ30358337-60D6C434-06D2-4527-8D81-D54F209064E5Q30370745-5ECB046C-4353-40D9-9FFD-11892266955BQ30527797-2FE39A9E-7880-4C77-8055-FA056139A86CQ30578597-A53FD7F5-2820-4398-B4DD-D400C19C811EQ30833019-518A8E8C-0EBF-4DB3-9686-E2FD5F32F959Q30841801-2EBBDE58-1CBF-4599-A3C2-37FB414D5D12Q31140102-2F4AF343-AB80-452B-8E17-34B833FEAC71Q31141124-D345B910-D5B2-4BFB-BCF3-282C14DA2D7EQ33366459-152AE2FC-9AA0-44CE-A86E-5686E2CEDE55Q33562458-8E0DB93B-6154-425C-8E11-AD4EEE4DF25EQ33637285-A3527910-AEC9-41DB-A453-8B8353E0748DQ33670282-C5FBFCFA-E5BD-4E4A-B8FB-11DA1C00B32AQ33870090-DFAF65A2-E7A6-4991-9739-B140031D2C2FQ33879213-B4170736-0E9F-417D-8C5F-C732D7B061CDQ33887363-DBAEB35F-073D-4EBC-8777-295F39D49200Q33894316-827CD249-8B10-41CD-B6D7-520A4169F274Q33896664-A4FFA586-2605-4D79-BFAC-605A93AA9FEAQ33926682-0C6635A8-B16B-48F4-AA43-6C3A20825FB7Q33933189-487C699A-7543-49C5-9EB3-C2724C5C8961Q33937968-FF9483AD-F180-4EE1-818E-02A35A535003Q34005558-D3DF6C94-22D8-453D-84BF-AAB80AD47B22Q34019751-6AD2B8F5-9B7D-4260-838C-EF8C89736795Q34037141-FB317046-0B0D-4811-B41D-D94CA14B16E4Q34044014-93C5CD86-F153-4349-9FAD-914F4723B8E8Q34111474-E20402AF-B1BF-4E37-A869-2F0ED3B9A53CQ34128361-02C72A4B-92AF-41E6-8DE7-AF5B026B416F
P2860
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@ast
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@en
type
label
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@ast
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@en
prefLabel
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@ast
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@en
P2093
P50
P1433
P1476
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
@en
P2093
A B Singleton
B M Ravina
C M Tanner
D J Brooks
DLB/PDD Working Group
P304
P356
10.1212/01.WNL.0000256715.13907.D3
P407
P577
2007-03-01T00:00:00Z